Bedel Financial Consulting, Inc. Alkermes Plc. Transaction History
Bedel Financial Consulting, Inc.
- $716 Million
- Q3 2024
Shares
2 transactions
Others Institutions Holding ALKS
# of Institutions
361Shares Held
181MCall Options Held
175KPut Options Held
96.6K-
Black Rock Inc. New York, NY29.1MShares$838 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$546 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD13MShares$374 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA12.7MShares$364 Million0.06% of portfolio
-
State Street Corp Boston, MA9.19MShares$264 Million0.01% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4.73B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...